Oncotarget

Research Papers:

Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes

Salvador Alonso _, Meng Su, Jace W. Jones, Sudipto Ganguly, Maureen A. Kane, Richard J. Jones and Gabriel Ghiaur

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:14905-14912. https://doi.org/10.18632/oncotarget.3614

Metrics: PDF 3054 views  |   HTML 3124 views  |   ?  


Abstract

Salvador Alonso1, Meng Su1, Jace W. Jones2, Sudipto Ganguly1, Maureen A. Kane2, Richard J. Jones1, Gabriel Ghiaur1

1Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University, Baltimore, MD, USA

2Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA

Correspondence to:

Gabriel Ghiaur, e-mail: [email protected]

Keywords: drug resistance, leukemia, microenvironment, CYP, multiple myeloma

Received: January 31, 2015     Accepted: March 14, 2015     Published: April 10, 2015

ABSTRACT

Substantial evidence now demonstrates that interactions between the tumor microenvironment and malignant cells are a critical component of clinical drug resistance. However, the mechanisms responsible for microenvironment-mediated chemoprotection remain unclear. We showed that bone marrow (BM) stromal cytochrome P450 (CYP)26 enzymes protect normal hematopoietic stem cells (HSCs) from the pro-differentiation effects of retinoic acid. Here, we investigated if stromal expression of CYPs is a general mechanism of chemoprotection. We found that similar to human hepatocytes, human BM-derived stromal cells expressed a variety of drug-metabolizing enzymes. CYP3A4, the liver’s major drug-metabolizing enzyme, was at least partially responsible for BM stroma’s ability to protect multiple myeloma (MM) and leukemia cells from bortezomib and etoposide, respectively, both in vitro and in vivo. Moreover, clarithromycin overcame stromal-mediated MM resistance to dexamethasone, suggesting that CYP3A4 inhibition plays a role in its ability to augment the activity of lenalidomide and dexamethasone as part of the BiRd regimen. We uncovered a novel mechanism of microenvironment-mediated drug resistance, whereby the BM niche creates a sanctuary site from drugs. Targeting these sanctuaries holds promise for eliminating minimal residual tumor and improving cancer outcomes.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3614